Table 2.
Selected studies.
| Reference | Study type | Country, region of origin cohort | N | QoL Questionnaires |
|---|---|---|---|---|
| Anagnostis et al. (21) | Case–controla | Greece, Thessaloniki | 40 | AcroQoL |
| Biermasz et al. (22) | Cohort, intervention | The Netherlands, Leiden | 14 | NHP |
| Biermasz et al. (23) | Case–controla | The Netherlands, Leiden | 118 | AcroQoL, SF36, NHP, MFI-20, HADS |
| Biermasz et al. (24) | Cohort | The Netherlands, Leiden | 118 | AcroQoL, SF36, NHP, MFI-20, HADS |
| Bonapart et al. (25) | Cohort, longitudinal | The Netherlands, Rotterdam | 14 | SF36 |
| Bronstein et al. (26) | Cohort, longitudinal | Brazil, multicenter trial | 119 | AcroQoL |
| Cannavo et al. (27) | Case–controla | Italy Messina | 56 | AcroQoL |
| Caron et al. (28) | Cohort, intervention | France, multicenter trial: 27 centers in 9 countries | 90 | AcroQoL |
| Caron et al. (29) | Cohort, intervention | France, multicenter trial: 27 centers in 9 countries | 90 | AcroQoL |
| Celik et al. (30) | Cohort | Turkey, Istanbul | 57 | AcroQoL |
| Celik and Kadioglu (31) | Cohort | Turkey, Istanbul | 57 | AcroQoL |
| Chin et al. (32), | Cohort, intervention | Korea, multicenter trial: 11 centers in Korea | 58 | AcroQoL |
| Dantas et al. (33) | Cohort | Brazil, Brasilia | 42 | SF36 |
| Fathalla et al. (34) | Cohort | Canada, Toronto | 20 | SF36, PIT QOL |
| Fujio et al. (35) | Cohort, intervention | Japan, Kagoshima | 41 | SF36 |
| Geraedts et al. (36) | Cohort, longitudinal | Germany, Munich | 80 | AcroQoL, SF36 |
| Ghigo et al. (37) | Cohort, intervention | Italy, multicenter trial: 50 centers in 13 countries | 113 | AcroQoL |
| Hatipoglu et al. (38) | Case–control, interventiona | Turkey, Istanbul | 20 | AcroQoL |
| Hatipoglu et al. (39) | Cohort | Turkey, Istanbul | 30 | AcroQoL |
| Hua et al. (9) | Cohort | Taiwan, Taipei | 52 | AcroQoL |
| Karaca et al. (40) | Cohort, intervention | Turkey, Kayseri | 22 | AcroQoL |
| Kauppinen-Makelin et al. (41) | Cohort | Finland, multicenter trial: 5 centers in Finland | 231 | 15D |
| Kepicoglu et al. (42) | Cohort | Turkey, Istanbul | 133 | AcroQoL |
| Leon-Carrion et al. (43) | Case–controla | Spain, multicenter trial: 4 centers in Spain | 34 | AcroQoL |
| Lombardi et al. (44) | Cohort, intervention | Italy, multicenter trial: 24 centers in Italy | 16 | NHP |
| Madsen et al. (45) | Cohort, intervention | Denmark, Aarhus | 51 | EuroQoL |
| Mangupli et al. (46) | Cohort, intervention | Venezuela, Caracas | 18 | AcroQoL |
| Matta et al. (47) | Cohort | France, Toulouse | 28 | AcroQoL |
| Milian et al. (48) | Cohort, intervention | Germany, Tuebingen | 93 | AcroQoL, SF36, QLS-H, SCL-90 |
| Miller et al. (49) | Cohort | United Kingdom, Oxford | 58 | AcroQoL, SF36, AIMS2 |
| Neggers et al. (50) | Cohort, intervention | The Netherlands, Rotterdam | 30 | AcroQoL |
| Paisley et al. (12) | Cohort, longidutinal | United Kingdom, Manchester | 56 | AcroQoL, EUroQoL, PGWB, SSS |
| Postma et al. (51) | Cohort | The Netherlands, multicenter trial: 2 centers in The Netherlands | 108 | AcroQoL, SF36, MFI-20, HADS |
| Psaras et al. (52) | Cohort | Germany, Tuebingen | 37 | AcroQoL, SF36, SCL-90-R |
| Psaras et al. (53) | Cohort | Germany, Tuebingen | 55 | AcroQoL, SF36 |
| Raappana et al. (54) | Cohort | Finland, Oulou | 22 | 15D |
| Roerink et al. (55) | Case–controla | The Netherlands, Nijmegen | 73 | AcroQoL, SF36 |
| Rowles et al. (56) | Cohort | United Kingdom, Manchester | 80 | AcroQoL, EuroQoL, PGWB, SSS |
| Rubeck et al. (57) | Cohort | Denmark, Aarhus | 63 | EuroQoL |
| Sardella et al. (58) | Cohort, longitudinal | Italy, Pisa | 23 | AcroQoL |
| Schopohl et al. (59), | Cohort | Germany, multicenter trial: 13 centers in Germany | 17 | AcroQoL |
| Siegel et al. (60) | Cohort | Germany, Aachen | 41 | AcroQoL, SF36 |
| T’Sjoen et al. (10) | Cohort | Belgium, multicenter trial: 37 centers in Belgium and Luxembourg | 291 | AcroQoL |
| Trainer et al. (61) | Cohort, intervention | United Kingdom, multicenter trial: 29 centers | 77 | AcroQoL, EuroQoL |
| Trepp et al. (13) | Cohort | Switzerland, Bern | 33 | AcroQoL |
| van der Klaauw et al. (62) | Cohort, longitudinal | The Netherlands, Leiden | 82 | AcroQoL, SF36, HADS, MFI-20 |
| Vandeva et al. (63) | Cohort, longitudinal | Bulgaria, Sofia | 212 | AcroQoL |
| Varewijck et al. (64) | Cohort | The Netherlands, Rotterdam | 15 | AcroQoL, SF36 |
| Wassenaar et al. (65) | Cohort | The Netherlands, Leiden | 58 | AcroQoL, SF36, MFI-20, HADS |
| Webb et al. (66) | Case–control, longitudinala | Spain, multicenter trial: 16 centers in Spain | 106 | AcroQoL, EuroQoL |
| Yoshida et al. (67) | Cohort | Japan, Kobe | 38 | AcroQoL |
aFor case–control studies, only the cohorts detailing patients with acromegaly were studied.